ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
As the most common subtype of lymphoma, diffuse large B-cell lymphoma (DLBCL) is an
aggressive but potentially curable malignancy. The poor prognosis of elderly DLBCL patients
may be related to the biological behavior of the disease, more comorbidities, poor
performance status, and inability to tolerate standard-intensity immunochemotherapy. The
investigators plan to use ZR2 regimen(rituximab, lenalidomide and zanubrutinib) for 2 cycles
followed by immunochemotherapy for up to 4 cycles in elderly newly diagnosed DLBCL patients.